دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Therapeutic targeting of the pituitary tumor microenvironment
doi : 10.1016/j.pharmthera.2023.108506
Volume 250, October 2023, 108506
The role of DNA methylation in personalized medicine for immune-related diseases
doi : 10.1016/j.pharmthera.2023.108508
Volume 250, October 2023, 108508
Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
Emanuel Raschi a,?, Manuela Casula b,c , Arrigo F.G. Cicero a,d , Alberto Corsini e , Claudio Borghi a,d , Alberico Catapano
doi : 10.1016/j.pharmthera.2023.108507
Volume 250, October 2023, 108507
Antithrombotic therapy following transcatheter aortic valve intervention
Harish Sharma a,b , Shazia Afzal c , Jürgen Leick c , Nikos Werner c , Sagar N. Doshi a,b,1 , M. Adnan Nadir
doi : 10.1016/j.pharmthera.2023.108509
Volume 250, October 2023, 108509
Anticancer drug delivery by focused ultrasound-mediated blood-brain/tumor barrier disruption for glioma therapy: From benchside to bedside
Charlotte Bérard a , Charles Truillet b , Benoit Larrat c , Frédéric Dhermain d , Marie-Anne Estève a , Florian Correard a , Anthony Novell
doi : 10.1016/j.pharmthera.2023.108518
Volume 250, October 2023, 108518
Repurposing of antiangiogenic agents for treatment of vascular anomalies
Julie Blatt a,?, Jennifer E. Brondon a , Elizabeth L. Nieman b , Kynlon Phillips c , Arti Pandya
doi : 10.1016/j.pharmthera.2023.108520
Volume 250, October 2023, 108520
Lactate acidosis and simultaneous recruitment of TGF-β leads to alter plasticity of hypoxic cancer cells in tumor microenvironment
Saumya Rastogi a , Shashank Shekher Mishra a , Mandeep Kumar Arora a , Gaurav Kaithwas b , Sugato Banerjee c , Velayutham Ravichandiran c , Subhadeep Roy c,??, Lakhveer Singh
doi : 10.1016/j.pharmthera.2023.108519
Volume 250, October 2023, 108519
Potential targeting of the tumor microenvironment to improve cancer virotherapy
Zi-Xian Liao a , Shan-hui Hsu b , Shiue-Cheng Tang c,d , Ivan Kempson e , Pan-Chyr Yang f , S. Ja Tseng
doi : 10.1016/j.pharmthera.2023.108521
Volume 250, October 2023, 108521
Towards precision medicine in migraine: Recent therapeutic advances and potential biomarkers to understand heterogeneity and treatment response
Gabriella Juhasz a,b,?, Kinga Gecse a,b,†, Daniel Baksa
doi : 10.1016/j.pharmthera.2023.108523
Volume 250, October 2023, 108523
Cancer metastasis: Molecular mechanisms and clinical perspectives
Sameer Ullah Khan a,b , Kaneez Fatima b,c , Fayaz Malik b,c,???, Halime Kalkavan d,e,??, Abubakar Wani
doi : 10.1016/j.pharmthera.2023.108522
Volume 250, October 2023, 108522
Medulloblastoma targeted therapy: From signaling pathways heterogeneity and current treatment dilemma to the recent advances in development of therapeutic strategies
Qiyue Wang a,1 , Xiaofei Xin b,1 , Qihao Dai a , Mengjuan Sun b , Jinhua Chen b , Ebrahim Mostafavi c,?, Yan Shen b,?, Xueming Li
doi : 10.1016/j.pharmthera.2023.108527
Volume 250, October 2023, 108527
Target protein degradation by protacs: A budding cancer treatment strategy
Diksha Choudhary a , Amritpal Kaur a , Pargat Singh a , Gaurav Chaudhary a , Rajwinder Kaur a,?, Mohammad F. Bayan b , Balakumar Chandrasekaran b,?, Saeed M. Marji b , Reema Ayman
doi : 10.1016/j.pharmthera.2023.108525
Volume 250, October 2023, 108525
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases
Maya Ezzo, Boris Hinz
doi : 10.1016/j.pharmthera.2023.108528
Volume 250, October 2023, 108528
Use of big data and machine learning algorithms to extract possible treatment targets in neurodevelopmental disorders
Muhammad Ammar Malik a , Stephen V. Faraone b , Tom Michoel a , Jan Haavik
doi : 10.1016/j.pharmthera.2023.108530
Volume 250, October 2023, 108530
Glyoxalase I is a novel target for the prevention of metabolic derangement
Edwin R. Miranda a,b , Jacob M. Haus
doi : 10.1016/j.pharmthera.2023.108524
Volume 250, October 2023, 108524
Therapeutic targeting of the pituitary tumor microenvironment
doi : 10.1016/j.pharmthera.2023.108506
Volume 250, October 2023, 108506
The role of DNA methylation in personalized medicine for immune-related diseases
doi : 10.1016/j.pharmthera.2023.108508
Volume 250, October 2023, 108508
Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
Emanuel Raschi a,?, Manuela Casula b,c , Arrigo F.G. Cicero a,d , Alberto Corsini e , Claudio Borghi a,d , Alberico Catapano
doi : 10.1016/j.pharmthera.2023.108507
Volume 250, October 2023, 108507
Antithrombotic therapy following transcatheter aortic valve intervention
Harish Sharma a,b , Shazia Afzal c , Jürgen Leick c , Nikos Werner c , Sagar N. Doshi a,b,1 , M. Adnan Nadir
doi : 10.1016/j.pharmthera.2023.108509
Volume 250, October 2023, 108509
Anticancer drug delivery by focused ultrasound-mediated blood-brain/tumor barrier disruption for glioma therapy: From benchside to bedside
Charlotte Bérard a , Charles Truillet b , Benoit Larrat c , Frédéric Dhermain d , Marie-Anne Estève a , Florian Correard a , Anthony Novell
doi : 10.1016/j.pharmthera.2023.108518
Volume 250, October 2023, 108518
Repurposing of antiangiogenic agents for treatment of vascular anomalies
Julie Blatt a,?, Jennifer E. Brondon a , Elizabeth L. Nieman b , Kynlon Phillips c , Arti Pandya
doi : 10.1016/j.pharmthera.2023.108520
Volume 250, October 2023, 108520
Lactate acidosis and simultaneous recruitment of TGF-β leads to alter plasticity of hypoxic cancer cells in tumor microenvironment
Saumya Rastogi a , Shashank Shekher Mishra a , Mandeep Kumar Arora a , Gaurav Kaithwas b , Sugato Banerjee c , Velayutham Ravichandiran c , Subhadeep Roy c,??, Lakhveer Singh
doi : 10.1016/j.pharmthera.2023.108519
Volume 250, October 2023, 108519
Potential targeting of the tumor microenvironment to improve cancer virotherapy
Zi-Xian Liao a , Shan-hui Hsu b , Shiue-Cheng Tang c,d , Ivan Kempson e , Pan-Chyr Yang f , S. Ja Tseng
doi : 10.1016/j.pharmthera.2023.108521
Volume 250, October 2023, 108521
Towards precision medicine in migraine: Recent therapeutic advances and potential biomarkers to understand heterogeneity and treatment response
Gabriella Juhasz a,b,?, Kinga Gecse a,b,†, Daniel Baksa
doi : 10.1016/j.pharmthera.2023.108523
Volume 250, October 2023, 108523
Cancer metastasis: Molecular mechanisms and clinical perspectives
Sameer Ullah Khan a,b , Kaneez Fatima b,c , Fayaz Malik b,c,???, Halime Kalkavan d,e,??, Abubakar Wani
doi : 10.1016/j.pharmthera.2023.108522
Volume 250, October 2023, 108522
Medulloblastoma targeted therapy: From signaling pathways heterogeneity and current treatment dilemma to the recent advances in development of therapeutic strategies
Qiyue Wang a,1 , Xiaofei Xin b,1 , Qihao Dai a , Mengjuan Sun b , Jinhua Chen b , Ebrahim Mostafavi c,?, Yan Shen b,?, Xueming Li
doi : 10.1016/j.pharmthera.2023.108527
Volume 250, October 2023, 108527
Target protein degradation by protacs: A budding cancer treatment strategy
Diksha Choudhary a , Amritpal Kaur a , Pargat Singh a , Gaurav Chaudhary a , Rajwinder Kaur a,?, Mohammad F. Bayan b , Balakumar Chandrasekaran b,?, Saeed M. Marji b , Reema Ayman
doi : 10.1016/j.pharmthera.2023.108525
Volume 250, October 2023, 108525
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases
Maya Ezzo, Boris Hinz
doi : 10.1016/j.pharmthera.2023.108528
Volume 250, October 2023, 108528
Use of big data and machine learning algorithms to extract possible treatment targets in neurodevelopmental disorders
Muhammad Ammar Malik a , Stephen V. Faraone b , Tom Michoel a , Jan Haavik
doi : 10.1016/j.pharmthera.2023.108530
Volume 250, October 2023, 108530
Glyoxalase I is a novel target for the prevention of metabolic derangement
Edwin R. Miranda a,b , Jacob M. Haus
doi : 10.1016/j.pharmthera.2023.108524
Volume 250, October 2023, 108524
